Citius Pharmaceuticals, dedicated to the development and commercialization of critical care products
Myron Holubiak, President and CEO of Citius Pharmaceuticals, and Leonard Mazur, Chairman of the Board at Citius Pharmaceuticals, a specialty late-stage pharmaceutical company dedicated to the development and commercialization of critical care products with a focus on anti-infectives and cancer care joins eHealth Radio and the Cancer Information and Health News Channels.
Listen to interview with host Eric Michaels and guests Myron Holubiak & Leonard Mazur discuss the following:
Please give us an overview of catheter-related bloodstream infections (CRBSIs) and central venous catheters (CVCs).
Who is at Risk for Catheter-Related Bloodstream Infections (CRBSIs)?
Please give us a brief description of Minolok and how does it help the standard of care in the management of CRBSIs?
Give us a brief description of our NoveCite subsidiary and the impact of Covid 19 patients w ARDS. What is your technology and why is it different?
How is the development of MinoWrap for mastectomies progressing after your collaboration w MD Andersen?
Why did the both of you invest 26.5 million into the company?
Mr. Mazur is an accomplished entrepreneur and pharmaceutical industry executive with notable accomplishments in founding, building and creating value and returns for investors. Mr. Mazur was the Chairman of Leonard Meron Biosciences, Inc. prior to its merger with Citius in March 2016. He is the cofounder and Vice Chairman of Akrimax Pharmaceuticals, LLC (“Akrimax”), a privately held pharmaceutical company specializing in producing cardiovascular and general pharmaceutical products. Akrimax was founded in September 2008, and has successfully launched prescription drugs while acquiring drugs from major pharmaceutical companies. From January 2005 to May 2012, Mr. Mazur also co-founded and served as the Chief Operating Officer of Triax Pharmaceuticals LLC (“Triax”), a specialty pharmaceutical company producing prescription dermatological drugs. Prior to joining Triax, he was the founder, and, from 1995 to 2005, Chief Executive Officer, of Genesis Pharmaceuticals, Inc. (“Genesis”), a dermatological products company that marketed its products through dermatologists’ offices, and co-promoted products for major pharmaceutical companies. In 2003, Mr. Mazur successfully sold Genesis to Pierre Fabre, a leading pharmaceutical company.
Mr. Mazur has extensive sales, marketing and business development experience from his tenures at Medicis Pharmaceutical Corporation, as Executive Vice President, ICN Pharmaceuticals, Inc., as Vice President, Sales & Marketing, Knoll Pharma (a division of BASF), and Cooper Laboratories, Inc.
Mr. Mazur is a member of the Board of Trustees of Manor College, and is a recipient of the Ellis Island Medal of Honor. Mr. Mazur received both his BA and MBA from Temple University, and has served in the US Marine Corps Reserves.
Mr. Holubiak has extensive experience in managing and leading both large and emerging pharmaceutical and life sciences companies. Mr. Holubiak was co-founder, director and CEO of Leonard Meron Biosciences, Inc. prior to its merger with Citius in March 2016. Mr. Holubiak was the President of Roche Laboratories, Inc. (“Roche”), a major research-based pharmaceutical company, from December 1998 to August 2001.
Prior to that, he held sales and marketing positions at Roche during his 19-year tenure there. As President of Roche, Mr. Holubiak helped transform Roche Labs into a leading antibiotic and biotechnology company. He was also founder of Emron, Inc., a health economics and managed care consulting company, and helped to create the Academy of Managed Care Pharmacy (AMCP). Mr. Holubiak was also a director of Bioscrip, Inc., a national home infusion company, from 2002 through 2016, and served as its Chairman of the Board from 2012 through 2016.
Since July 2010, Mr. Holubiak has served as a member of the Board of Directors of Assembly Biosciences, Inc. (“Assembly”) and its predecessor, Ventrus Biosciences, Inc. Mr. Holubiak is also a trustee of the Academy of Managed Care Pharmacy Foundation. He received a BS in Molecular Biology and Biophysics from the University of Pittsburgh; he received advanced business training from the Harvard Business School and the University of London, as well as advanced training in health economics from the University of York’s Centre for Health Economics.